



U.S. Pharmacopeia
The Standard of QualitySM

December 20, 2011

Dear Colleague:

This is a notification to USP's valued customers about the discontinuance of Chlorpheniramine Maleate Extended-Release Tablets RS.

Effective February 1, 2012, USP will remove Chlorpheniramine Maleate Extended-Release Tablets RS from the Apparatus 3 Performance Verification Test Apparatus Suitability section of General Chapter <711> Dissolution.

The change is necessary because Chlorpheniramine Maleate Extended-Release Tablets RS Lot G1J218 will be depleted and no suitable replacement candidate has been found to date. With no suitable replacement candidate for Lot G1J218, USP wishes to avoid placing laboratories into a circumstance of being unable to demonstrate conformance with the General Chapter <711> because they cannot obtain the material .

USP remains convinced that a PVT is a critical element in the qualification of in vitro performance test equipment. USP will continue to seek a material which can serve as the PVT for Apparatus 3.

The certificate provided with 1123102 Chlorpheniramine Maleate Extended-Release Tablets RS, Lot G1J218 is valid until February 28, 2014.

Questions about this USP Reference Standard can be addressed to Reference Standard Technical Service at RSTech@USP.ORG .

Headquarters
12601 Twinbrook Parkway
Rockville, Maryland 20852
+1-301-881-0666

Europe/Middle East/Africa
Münchensteinerstrasse 41
CH-4052 Basel, Switzerland
+41 (0)61 316 30 10

USP-India Private Limited
IKP Knowledge Park
Turkapally Village
Genome Valley
Shameerpet, Ranga Reddy District
Hyderabad 500 078, A.P., India
+91-40-2348-0088

USP-China
Building 11, Lane 67 Libing Road,
Zhangjiang Hi-Tech Park
201203 Shanghai
China
+86-21-51370600

USP-Brazil
Avenida Ceci, 1600 - Tamboré
Barueri-SP
06460-120
Brazil
+ 55 -11-3245-6400

www.usp.org

Sincerely,

Steven Paul
Marketing Director, Pharmaceuticals
STP@USP.ORG
301-816-8210